INVESTOR REMINDER NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
November 12, 2018 09:10 ET
|
Schall Law
LOS ANGELES, Nov. 12, 2018 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AbbVie Inc. (“AbbVie” or...
INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
November 05, 2018 14:40 ET
|
Schall Law
LOS ANGELES, Nov. 05, 2018 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AbbVie Inc. (“AbbVie” or...
IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
October 29, 2018 14:03 ET
|
Schall Law
LOS ANGELES, Oct. 29, 2018 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AbbVie Inc. (“AbbVie” or...
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
October 23, 2018 15:22 ET
|
Schall Law
LOS ANGELES, Oct. 23, 2018 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AbbVie Inc. (“AbbVie” or...
Voyager Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
March 14, 2018 07:02 ET
|
Voyager Therapeutics, Inc.
VY-AADC for advanced Parkinson’s disease on track for start of planned global, pivotal Phase 2-3 program during the middle of this year Two IND filings expected from the ALS, Huntington’s disease and...
Voyager Therapeutics and AbbVie Announce Global Strategic Collaboration to Develop Potential New Treatments for Alzheimer’s Disease and Other Tau-Related Neurodegenerative Diseases
February 20, 2018 07:00 ET
|
Voyager Therapeutics, Inc.
Collaboration to include development of gene therapies consisting of vectors to deliver monoclonal antibodies to the brain directed against tau Voyager to receive $69 million upfront payment and...
INVESTORS SAY EXECUTIVE PAY PACKAGES AT PHARMA MAY INCENTIVIZE DRUG PRICING RISKS
December 13, 2017 13:13 ET
|
Azzad Funds
Falls Church, Dec. 13, 2017 (GLOBE NEWSWIRE) -- SOURCE - AZZAD ASSET MANAGEMENT Investors today announced they have filed resolutions at five major pharmaceutical companies asking for information...
ABC Life Literacy Canada engages Canadians to increase their health literacy with ABC Health Matters
June 07, 2017 11:35 ET
|
ABC Life Literacy Canada
Toronto, Ontario, June 07, 2017 (GLOBE NEWSWIRE) -- ABC Life Literacy Canada (ABC) is proud to announce the second year of ABC Health Matters, a health literacy program developed to help Canadians...
Agile Therapeutics to Present Additional Phase 3 Data at the 2017 Annual Clinical and Scientific Meeting of the American Congress of Obstetricians and Gynecologists
May 03, 2017 16:15 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., May 03, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company today announced that data from its Phase 3 SECURE study will be presented at...
Agile Therapeutics Receives Approximately $3 Million in Non-Dilutive Funding from New Jersey’s Technology Business Tax Certificate Transfer Program
December 01, 2016 08:00 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Dec. 01, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women’s health specialty pharmaceutical company announced today that it has received net proceeds of...